Marksans Pharma profit climbs 60% on standalone basis for FY26
The company reported a consolidated net profit of ₹4,201 million for the year, alongside a final dividend recommendation of ₹0.90 per share.
— 1 earlier story on Marksans Pharma Ltd. →What's new
- Standalone profit after tax rose nearly 60% to ₹3,007m.
- Consolidated profit grew 10% to ₹4,201m.
- Board recommended a final dividend of ₹0.90 per share.
Why this matters
The gap between standalone and consolidated profit growth suggests varying performance across subsidiaries. An unmodified audit opinion provides comfort, but the market has largely priced in these trends through quarterly disclosures.
What we're watching
- Shareholder approval for the proposed dividend at the AGM.
- Sustainability of foreign exchange gains in the current fiscal year.
- Margin trends in the upcoming quarterly results.
The full read
Marksans Pharma closed FY26 with a 60% jump in standalone profit after tax to ₹3,007 million, while consolidated profit grew 10% to ₹4,201 million. Revenue growth remained steady at 14% on a standalone basis and 12.5% on a consolidated basis. The board recommended a final dividend of ₹0.90 per share, pending shareholder approval. These results are consistent with the quarterly trends already visible to the market.
Routine.
The auditor provided an unmodified opinion, confirming the integrity of the reported figures. While the standalone profit growth is eye-catching, the consolidated performance provides a more grounded view of the company's annual trajectory. The next test for the company is maintaining this revenue momentum without relying on the foreign exchange gains that helped lift this year's bottom line.
Questions answered
- How did standalone performance compare to consolidated results?
- Standalone profit jumped nearly 60% to ₹3,007 million, while consolidated profit grew by a more modest 10% to ₹4,201 million.
- What drove the profit growth?
- The company attributes the performance to higher revenue and foreign exchange gains during the fiscal year.
- What is the dividend payout for shareholders?
- The board has recommended a final dividend of ₹0.90 per share, which remains subject to approval at the upcoming annual general meeting.
- Are there any concerns regarding the audit?
- No. The auditor issued an unmodified opinion, confirming the quality of the financial reporting.
Story so far
All notes on MARKSANS →- 26 May 2026 · 12:56 PM IST Marksans Pharma profit climbs 60% on standalone basis for FY26
- today Marksans Pharma profit jumps 60% on standalone basis for FY26